Le Lézard
Classified in: Health, Science and technology

Reverba Reaffirms Commitment to Patient Data Security and Privacy with Ongoing SOC 2®, Type II Certification Since 2016


Reverba, a leading global patient engagement company, announces that it has successfully reaffirmed the Service Organization Control (SOC) 2, Type II certification for 2022, completing this important security audit for the sixth time and maintaining its certification continuously since 2016. To comply with SOC2, Reverba demonstrated it has established and utilizes rigorous policies and procedures for security and confidentiality in its data processing systems and with subcontractors and vendors, maintaining the highest level of data security and compliance.

Over the last 20 years of innovating in patient engagement, data privacy and security have become a central concern for pharmaceutical companies and the patient they serve. Reverba provides custom data- and technology-driven solutions for patient engagement, empowering biopharmaceutical companies to connect with patients as they advance their products throughout the product lifecycle, so having this designation allows Reverba to ensure compliance while making patient-centered action possible for their clients.

"We're incredibly proud of this accomplishment. SOC 2, Type II certification touches on all aspects of our business operations, and it creates an important level of trust between Reverba and the biopharmaceutical companies who rely on us to provide patient engagement solutions," said Cheryl Lubbert, CEO and co-founder of Reverba. "Reverba is unique as a company dedicated solely to patient engagement that prioritized this certification early on. Maintaining our SOC 2, Type II certification since 2016 reinforces our ongoing commitment to the security, compliance and processing integrity of our platform and solutions."

This widely recognized auditing standard was developed by the American Institute of Certified Public Accountants (AICPA). Reverba's SOC 2 audit was conducted by Moss Adams, a top 15 independent auditor with over 100 years in business including serving as an independent expert in security testing and compliance certifications for service companies worldwide. Reverba maintains SOC 2, Type II certification in accordance with AICPA Attestation Standards and IAASB ISAE No. 3000 (Revised) Standards.

A copy of Reverba's SOC 2, Type II report is available to clients and prospects upon request.

About Reverba:

Reverba is a global patient engagement company that creates transformative tech-enabled solutions to build a bridge between patients and biopharma companies, from clinical development through commercialization. Through its Clinical and Commercial divisions, Reverba creates comprehensive custom patient engagement solutions using its proprietary reverbaBRIDGEtm technology platform and reverbaCONNECTtm foundational services. Reverba infuses compliance throughout all of its technology platforms and patient engagement solutions, maintaining SOC 2, Type II certification for the highest level of security. For more information, visit www.reverba.com or contact [email protected]


These press releases may also interest you

at 12:30
New data presented in two separate oral presentations at the European Association for the Study of the Liver's International Liver Congress 2022 (EASL ILC 2022)Following 90 days of dosing, ATI-2173, in combination with tenofovir disoproxil fumarate...

at 11:54
With its ruling today, the U.S. Supreme Court has overturned Roe v. Wade, dismantling the constitutional right to abortion that has stood for nearly 50 years. Roe is overturned at a time when 26 states are poised to ban abortion which will leave 36...

at 11:22
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Apyx Medical Corporation between May 12, 2021 and March 11, 2022, both dates inclusive (the "Class Period"), of the important August 5, 2022 lead...

at 09:05
Ionis Pharmaceuticals, Inc. , today...

at 04:05
AB-729, our RNAi therapeutic, provided robust and comparable HBsAg declines in both HBeAg+ and HBeAg- patients 50% (16 out of 32) of patients maintained HBsAg levels below 100 IU/mL 24 weeks after their last AB-729 dose In the first five patients...

at 00:35
Sinovac Biotech Ltd. ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that the South African Health Products Regulatory Authority (SAHPRA) granted conditional registration to SINOVAC CoronaVac®...



News published on 24 may 2022 at 08:05 and distributed by: